The possible involvement of mitochondrial dysfunctions in lewy body dementia: A systematic review

Functional Neurology

Volumn 30, Issue 3, 2015, Pages 151-158

  Spano, Mariangela ^a   Signorelli, Maria ^b   Vitaliani, Roberta ^a   Aguglia, Eugenio ^b   Giometto, Bruno ^a  

^a Department of Mental Health ^*  (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

Alpha synuclein; Dementia with Lewy bodies; Mitochondria; Neurodegenerative diseases; Parkinson s disease; ROS

Indexed keywords

ALPHA SYNUCLEIN; CALCIUM CHANNEL L TYPE; DJ 1 PROTEIN; KALLIKREIN 6; LEUCINE RICH REPEAT KINASE 2; MITOCHONDRIAL DNA; OUTER MEMBRANE PROTEIN; PARKIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; REACTIVE OXYGEN METABOLITE; SERINE PROTEINASE OMI;

APOPTOSIS; BIBLIOGRAPHIC DATABASE; DEGENERATIVE DISEASE; DIFFUSE LEWY BODY DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA DAMAGE; ENERGY METABOLISM; GENE EXPRESSION REGULATION; GENETIC POLYMORPHISM; HUMAN; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL PERMEABILITY; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN AGGREGATION; PROTEIN HOMEOSTASIS; PROTEIN LOCALIZATION; PROTEIN POLYMERIZATION; REVIEW; SYSTEMATIC REVIEW (TOPIC); BRAIN; GENETICS; METABOLISM; MITOCHONDRION; MUTATION; PATHOLOGY;

ALPHA-SYNUCLEIN; BRAIN; HUMANS; LEWY BODY DISEASE; MITOCHONDRIA; MUTATION;

EID: 84944451308     PISSN: 03935264     EISSN: 19713274     Source Type: Journal    
DOI: 10.11138/fneur/2015.30.3.151     Document Type: Review

References (73)

1. Aminoff JM, Boller F, Swaab FD (2008). The Dementias. Foreword. Handb Clin Neurol 89:7
2. Ahlskog JE (2009). Parkin and PINK1 parkinsonism may represent nigral mitochondrial cytopathies distinct from Lewy body Parkinson’s disease. Parkinsonism Relat Disord 15:721-727.
3. Beal MF (2005). Mitochondria take center stage in aging and neurodegeneration. Ann Neurol 58:495-505.
4. Bellani S, Sousa VL, Ronzitti G, et al. (2010). The regulation of synaptic function by alpha-synuclein. Commun Integr Biol 3:106-109.
5. Bogaerts V, Theuns J, van Broeckhoven C (2008). Genetic findings in Parkinson’s disease and translation into treatment: a leading role for mitochondria? Genes Brain Behav 7:129-151.
6. Branco DM, Arduino DM, Esteves AR, et al (2010). Cross-talk between mitochondria and proteasome in Parkinson’s disease pathogenesis. Front Aging Neurosci 2:17.
7. Chandra S, Fornai F, Kwon HB, et al (2004). Double-knockout mice for alpha-and beta-synucleins: effect on synaptic functions. Proc Natl Acad Sci U S A 101:14966-14971.
8. Chen S, Owens GC, Edelman DB (2008). Dopamine inhibits mitochondrial motility in hippocampal neurons. PLoS One 3:e2804.
9. Clark IE, Dodson MW, Jiang C, et al (2006). Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 441:1162-1166.
10. Cookson MR, van der Brug M (2008). Cell systems and the toxic mechanism(s) of alpha-synuclein. Exp Neurol 209:5-11.
11. Cookson MR (2006). Hero versus antihero: the multiple roles of alpha-synuclein in neurodegeneration. Exp Neurol 199: 238-242.
12. Cookson MR (2005). The biochemistry of Parkinson’s disease. Annu Rev Biochem 74:29-52.
13. Cooper AA, Gitler AD, Cashikar A, et al (2006). Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson’s models. Science 313:324-328.
14. Cullen V, Lindfors M, Ng J, et al (2009). Cathepsin D expression level affects alpha-synuclein processing, aggregation, and toxicity in vivo. Mol Brain 2:5.
15. de Castro IP, Martins LM, Loh SH (2011). Mitochondrial quality control and Parkinson’s disease: a pathway unfolds. Mol Neurobiol 43:80-86.
16. Detmer SA, Chan DC (2007). Functions and dysfunctions of mitochondrial dynamics. Nat Rev Mol Cell Biol 8:870-879.
17. Dickson DW, Schmidt ML, Lee VM, et al (1994). Immunoreac -tivity profile of hippocampal CA2/3 neurites in diffuse Lewy body disease. Acta Neuropathol 87:269-276.
18. Dickson DW, Ruan D, Crystal H, et al (1991). Hippocampal degeneration differentiates diffuse Lewy body disease (DLBD) from Alzheimer’s disease: light and electron microscopic immunocytochemistry of CA2-3 neurites specific to DLBD. Neurology 41:1402-1409.
19. DiMauro S (2007). Mitochondrial DNA medicine. Biosci Rep 27: 5-9.
20. Duda JE, Lee VM, Trojanowski JQ (2000). Neuropathology of synuclein aggregates. J Neurosci Res 61:121-127.
21. Ellis RJ, Minton AP (2006). Protein aggregation in crowded environments. Biol Chem 387:485-497.
22. Elkon H, Don J, Melamed E, et al (2002). Mutant and wild-type alpha-synuclein interact with mitochondrial cytochrome C oxidase. J Mol Neurosci 18:229-238.
23. Esteves AR, Arduíno DM, Silva DF et al (2011). Mitochondrial dysfunction: the road to alpha-synuclein oligomerization in PD. Parkinsons Dis 2011:693761.
24. Federico A, Cardaioli E, Da Pozzo P, et al (2012). Mitochondria, oxidative stress and neurodegeneration. J Neurol Sci 322:254-262.
25. Filosto M, Tomelleri G, Tonin P, et al (2007). Neuropathology of mitochondrial diseases. Biosci Rep 27:23-30.
26. Frank S (2006). Dysregulation of mitochondrial fusion and fission: an emerging concept in neurodegeneration. Acta Neuropathol 111:93-100.
27. Gardner JL, Craven L, Turnbull DM, et al (2007). Experimental strategies towards treating mitochondrial DNA disorders. Biosci Rep 27:139-150.
28. Goedert M (2001). Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2:492-501.
29. Green DR, Kroemer G (2004). The pathophysiology of mitochondrial cell death. Science 305:626-629.
30. Greene JC, Whitworth AJ, Kuo I, et al (2003). Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc Natl Acad Sci USA 100: 4078-4083.
31. Hansen LA, Masliah E, Terry RD, et al (1989). A neuropathological subset of Alzheimer’s disease with concomitant Lewy body disease and spongiform change. Acta Neuropathol 78:194-201.
32. Hashimoto M, Rockenstein E, Crews L, et al (2003). Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer’s and Parkinson’s diseases. Neuromolecular Med 4:21-36.
33. Hashimoto M, Masliah E (1999). Alpha-synuclein in Lewy body disease and Alzheimer’s disease. Brain Pathol 9:707-720.
34. Hettiarachchi NT, Parker A, Dallas ML, et al (2009). Alpha-synuclein modulation of Ca2+ signaling in human neuroblastoma (SH-SY5Y) cells. J Neurochem 111:1192-1201.
35. Höglinger GU, Oertel WH, Hirsch EC (2006). The rotenone model of parkinsonism -the five years inspection. J Neural Transm Suppl (70):269-272.
36. Hsu LJ, Sagara Y, Arroyo A, et al (2000). Alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol 157:401-410.
37. Iwata A, Maruyama M, Akagi T, et al (2003). Alpha-synuclein degradation by serine protease neurosin: implication for pathogenesis of synucleinopathies. Hum Mol Genet 12: 2625-2635.
38. Jackson DM, Westlind-Danielsson A (1994). Dopamine receptors: molecular biology, biochemistry and behavioural aspects. Pharmacol Ther 64:291-370.
39. Kramer ML, Scultz-Shaeffer WJ (2007). Presynaptic alphasynuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci 27:1405-1410.
40. Lashuel HA, Hartley D, Petre BM, et al (2002). Neurodege -nerative disease: amyloid pores from pathogenic mutations. Nature 418:291.
41. Lee YJ, Jeong SY, Karbowski M, et al (2004). Roles of the mammalian mitochondrial fission and fusion mediators Fis1, Drp1, and Opa1 in apoptosis. Mol Biol Cell 15:5001-5011.
42. Lee V, Goedert M, Trojanowski JQ (2001). Neurodegenerative tauopathies. Annu Rev Neurosci 24:1121-1159.
43. Lin MT, Beal MF (2006). Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443: 787-795.
44. Mandemakers W, Morais VA, De Strooper B (2007). A cell biological perspective on mitochondrial dysfunction in Parkinson disease and other neurodegenerative diseases. J Cell Sci 120:1707-1716.
45. MacLeod D, Dowman J, Hammond R, et al (2006). The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 52:587-593.
46. Mizushima N, Levine B, Cuervo AM, et al (2008). Autophagy fights disease through cellular self-digestion. Nature 451:1069-1075.
47. Mosharov EV, Staal RG, Bové J, et al (2006). Alpha-synuclein overexpression increases cytosolic catecholamine concentration. J Neurosci 26:9304-9311.
48. Mukaetova-Ladinska EB, McKeith IG (2006). Pathophysiology of synuclein aggregation in Lewy body disease. Mech Ageing Dev 127:188-202.
49. Navarro A, Boveris A (2010). Brain mitochondrial dysfunction in aging, neurodegeneration, and Parkinson’s disease. Front Aging Neurosci 2.
50. Ott M, Gogvadze V, Orrenius S, et al (2007). Mitochondria, oxidative stress and cell death. Apoptosis 12:913-922.
51. Palacino JJ, Sagi D, Goldberg MS, et al (2004). Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem 279:18614-18622.
52. Park J, Lee SB, Lee S, et al (2006). Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 441:1157-1161.
53. Perry G, Nunomura A, Hirai K, et al (2002). Is oxidative damage the fundamental pathogenic mechanism of Alzheimer’s and other neurodegenerative diseases? Free Radic Biol Med 33:1475-1479.
54. Petit-Paitel A (2010). [GSK-3beta: a central kinase for neurodegenerative diseases?]. Med Sci (Paris) 26:516-521.
55. Rodríguez-Navarro JA, Gómez A, Rodal I, et al. (2008). Parkin deletion causes cerebral and systemic amyloidosis in human mutated tau over-expressing mice. Hum Mol Genet 17:3128-3143.
56. Schulz-Schaeffer WJ (2010). The synaptic pathology of alphasynuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia. Acta Neuropathol 120:131-143.
57. Silvestri L, Caputo V, Bellacchio E, et al (2005). Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism. Hum Mol Genet 14:3477-3492.
58. Smith MA, Silva MD, Araujo LQ, et al (2005). Frequency of Werner helicase 1367 polymorphism and age-related morbidity in an elderly Brazilian population. Braz J Med Biol Res 38:1053-1059.
59. Soong NW, Hinton DR, Cortopassi G, et al (1992). Mosaicism for a specific somatic mitochondrial DNA mutation in adult human brain. Nat Genet 2:318-323.
60. Spillantini MG, Crowther RA, Jakes R, et al (1998). Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 95:6469-6473.
61. Sterky FH (2012). Mitochondrial dysfunction in dopamine neurons: implications for Parkinson’s disease. Stockholm, Karolinska Institute.
62. Surmeier DJ, Guzman JN, Sanchez-Padilla J, et al (2011). The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson’s disease. Neuroscience 198:221-231.
63. Taira T, Saito Y, Niki T, et al (2004). DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep 5: 213-218.
64. Tatebe H, Watanabe Y, Kasai T, et al (2010). Extracellular neurosin degrades α-synuclein in cultured cells. Neurosci Res 67:341-346.
65. Thomas B, Beal MF (2007). Parkinson’s disease. Hum Mol Genet 16 Spec No. 2:R183-194.
66. Ved R, Saha S, Westlund B, et al (2005). Similar patterns of mitochondrial vulnerability and rescue induced by genetic modification of alpha-synuclein, parkin, and DJ-1 in Caenorhabditis elegans. J Biol Chem 280:42655-42668.
67. Volles MJ, Lansbury PT Jr (2003). Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson’s disease. Biochemistry 42:7871-7878.
68. Wang C, Youle RJ (2009). The role of mitochondria in apoptosis. Annu Rev Genet 43:95-118.
69. Waxman EA, Giasson B (2009) Molecular mechanisms of α-synuclein neurodegeneration. Biochim Biophys Acta 1792, 616-624.
70. Xilouri M, Brekk OR, Stefanis L (2013). α-synuclein and protein degradation systems: a reciprocal relationship. Mol Neurobiol 47:537-551.
71. Yang Y, Gehrke S, Haque ME, et al (2005). Inactivation of Drosophila DJ-1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase/Akt signaling. Proc Natl Acad Sci USA 102:13670-13675.
72. Youle RJ, Karbowski M (2005). Mitochondrial fission in apoptosis. Nat Rev Mol Cell Biol 6:657-663.
73. Yu H, Saura CA, Choi SY, et al (2001). APP processing and synaptic plasticity in presenilin-1 conditional knockout mice. Neuron 31:713-726.